# Efficacy and Safety of Slenyto for Insomnia in Children With ASD

> **NCT04233502** · PHASE3 · WITHDRAWN · sponsor: **Neurim Pharmaceuticals Ltd.**

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Melatonin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04233502
- **Lead sponsor:** Neurim Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-09
- **Primary completion:** 2022-09
- **Final completion:** 2022-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was not initiated it was decided to cancel this study
- **Last updated:** 2021-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233502, "Efficacy and Safety of Slenyto for Insomnia in Children With ASD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04233502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*